Changes in serum levels of prostatic acid phosphatase and prostate specific antigen after luteinizing hormone-releasing hormone analogue administration in patients with metastatic prostatic cancer in relation to glandular differentiation

Int Urol Nephrol. 1995;27(6):769-74. doi: 10.1007/BF02552145.

Abstract

Eighteen previously untreated patients with metastatic carcinoma of the prostate were treated with LHRH analogue. They were divided into 3 groups according to the degree of glandular differentiation. In all groups, a transient rise of PAP and PSA was observed after the LH and testosterone surge. However, relative values of LH, testosterone, PAP and PSA did not differ significantly among the 3 groups. These facts suggest that a transient rise of PAP and PSA is caused by testosterone surge independently from the degree of glandular differentiation after LHRH analogue administration in patients with advanced prostatic cancer.

MeSH terms

  • Acid Phosphatase / blood*
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents, Hormonal / therapeutic use*
  • Humans
  • Leuprolide / therapeutic use*
  • Luteinizing Hormone / blood
  • Male
  • Middle Aged
  • Neoplasm Metastasis
  • Neoplasms, Hormone-Dependent / blood
  • Neoplasms, Hormone-Dependent / drug therapy*
  • Neoplasms, Hormone-Dependent / pathology
  • Prognosis
  • Prostate / enzymology*
  • Prostate-Specific Antigen / blood*
  • Prostatic Neoplasms / blood
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / pathology
  • Testosterone / blood

Substances

  • Antineoplastic Agents, Hormonal
  • Testosterone
  • Luteinizing Hormone
  • Acid Phosphatase
  • Prostate-Specific Antigen
  • Leuprolide